Core Viewpoint - DEMIRE Deutsche Mittelstand Real Estate AG has reported lower earnings for the first half of 2025 compared to the previous year, primarily due to opportunistic property sales, but the performance exceeded its own guidance [2][3]. Financial Performance - Rental income decreased by 21.7% to EUR 27.8 million in H1 2025, down from EUR 35.5 million in H1 2024 due to property sales [3][8]. - Earnings before interest and taxes (EBIT) fell to EUR -24.9 million in H1 2025, compared to EUR -14.1 million in H1 2024, largely due to write-downs on loans to Limes companies amounting to EUR -12.5 million [3]. - Funds from operations (FFO I) after taxes and before minority interests and interests on shareholder loans amounted to EUR 5.0 million in H1 2025, down from EUR 15.5 million in H1 2024 [4][8]. Property Sales and Portfolio Performance - The market value of DEMIRE's portfolio declined to approximately EUR 747.3 million as of 30 June 2025, down from EUR 779.3 million at the end of 2024, influenced by property sales and value adjustments [5]. - The net asset value (NAV) per share decreased by EUR 0.48 to EUR 1.97 in the reporting period [5]. - Letting performance improved, with 40,460 square meters leased in H1 2025 compared to 25,000 square meters in H1 2024, although the EPRA vacancy rate rose to 17.3% [5]. Debt and Liquidity Management - The net debt ratio (net LTV) was reported at 42.4%, slightly above the previous year's figure of 40.9% [6]. - Cash and cash equivalents decreased to EUR 34.9 million as of 30 June 2025, down from EUR 44.8 million at the end of 2024 [6]. - The company has initiated partial repayment of its corporate bond, with the outstanding nominal now at EUR 247.1 million [6]. Future Guidance - The company has raised its guidance for 2025, expecting rental income to be between EUR 52.0 million and EUR 54.0 million, up from the previous range of EUR 51.0 million to EUR 53.0 million [7][8]. - FFO I is now expected to be between EUR 5.0 million and EUR 7.0 million, an increase from the prior forecast of EUR 3.5 million to EUR 5.5 million [9].

Group 1 - Sampo plc has initiated a share buyback program with a maximum value of EUR 200 million, starting on 7 August 2025 [1][2] - On 13 August 2025, Sampo plc acquired a total of 330,528 A shares at a daily weighted average price of EUR 9.76 [1] - Following the transactions, Sampo plc owns a total of 1,646,806 A shares, representing 0.06% of the total number of shares [2] Group 2 - The share buyback program is in compliance with the Market Abuse Regulation (EU) 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 [1] - The authorization for the buyback program was granted by Sampo's Annual General Meeting on 23 April 2025 [1]

Core Viewpoint - Nilfisk's Q2 results indicate challenges and progress amid market caution and geopolitical uncertainties, with a slight decline in organic growth but stable gross margins and a focus on cost improvements and supply chain strengthening [1][4]. Financial Highlights - Revenue for Q2 2025 was 268.9 million EUR, down from 278.4 million EUR in Q2 2024, reflecting a decline of 9.5 million EUR [2][4]. - Organic growth was negative at -1.1% for Q2 2025, compared to a positive 2.4% in Q2 2024 [2][4]. - Gross margin remained stable at 42.0%, a slight decrease from 42.2% in the previous year [2][9]. - Overhead costs decreased to 92.2 million EUR from 94.2 million EUR year-on-year, with an overhead cost ratio of 34.3% [2]. - EBITDA before special items was 36.4 million EUR, down from 39.2 million EUR, resulting in an EBITDA margin of 13.5% [2][9]. - Free cash flow was negative at -16.3 million EUR, compared to a positive 8.4 million EUR in the same quarter last year [2][11]. Regional Performance - EMEA region showed organic growth of 0.7% in Q2 2025, driven by strong commercial execution and new products, although the Consumer Business faced declines [7]. - APAC reported moderate organic growth of 2.7%, while the Americas experienced negative growth of 4.9%, primarily due to soft demand and production capacity issues [8]. - Latin America continued to perform well with a strong growth rate of 14.0% [8]. Specialty and Consumer Business - The Specialty Business achieved robust organic growth of 10.8%, supported by strong sales in the US and demand for new products [5]. - The Consumer Business saw a decline of 5.1% due to weak demand in the high-pressure washer category [5]. Cost Management and Outlook - A cost reduction program was initiated in Q2 2025, leading to workforce reductions and expected gradual savings throughout 2025 and into 2026 [10]. - The financial outlook for 2025 remains unchanged, with organic growth expected between 1% and 3% and an EBITDA margin before special items projected between 13% and 14% [3].

Market Overview - The Shanghai Composite Index has surpassed 3700 points for the first time since December 2021, currently at 3702.61 points, up 0.52% [1] - The Shenzhen Component Index is at 11589.6 points, increasing by 0.33%, while the ChiNext Index is at 2504 points, rising by 0.3% [1] - Market trading volume has exceeded 800 billion, with an increase of over 101 billion compared to the same time yesterday [1] Sector Performance - The securities sector has shown significant volatility with Longcheng Securities achieving two consecutive gains [3] - Other sectors such as semiconductors, insurance, gaming, and hotel catering have also reported notable increases [3] - The FTSE China A50 Index futures have expanded their gains to 1.3% [3]

Financial Reporting Schedule - Marimekko Corporation will publish its Financial Statements and the Report of the Board of Directors for 2025 in week 13, at the latest [1] - The Financial Statements Bulletin for 2025 is scheduled for Thursday, 12 February 2026, at 8:00 a.m. [4] - Interim Reports for 2026 will be published on the following dates: 13 May 2026 for Q1, 13 August 2026 for H1, and 4 November 2026 for Q3 [4] Annual General Meeting - The Annual General Meeting is planned for Thursday, 16 April 2026, at 2 p.m. [2] - Shareholders can request agenda items for the meeting by sending a written request to the Board of Directors by 15 January 2026 [2] - An announcement regarding the resolutions of the Annual General Meeting will be released after the meeting [2] Company Overview - Marimekko is a Finnish lifestyle design company known for its original prints and colors, with a product portfolio that includes clothing, bags, accessories, and home décor items [3] - In 2024, Marimekko reported net sales of EUR 183 million and a comparable operating profit margin of 17.5 percent [3] - The company operates approximately 170 stores globally and serves customers in 39 countries through its online store, with key markets in Northern Europe, the Asia-Pacific region, and North America [3]

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals, Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor ( ...

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Core Insights - Zealand Pharma reported strong financial results for the first half of 2025, with revenue reaching DKK 9,096 million compared to DKK 49 million in the same period last year, indicating significant growth [4] - The collaboration with Roche on petrelintide is progressing well, with expectations for further updates at upcoming corporate events [6][7] - The company is well-positioned for future growth with key leadership appointments and a solid cash position of DKK 16,578 million as of June 30, 2025 [5][13] Financial Performance - Revenue for H1 2025 was DKK 9,096 million, a substantial increase from DKK 49 million in H1 2024 [4] - Operating expenses for H1 2025 were DKK 968 million, up from DKK 559 million in H1 2024, primarily due to increased R&D and transaction-related costs [4][5] - The operating result for H1 2025 was DKK 8,128 million, compared to a loss of DKK 524 million in H1 2024 [4] Collaboration and Development - Zealand Pharma's collaboration with Roche involves co-developing petrelintide, with a total deal consideration of USD 5.3 billion, including upfront cash payments of USD 1.65 billion [8] - The petrelintide program is advancing with Phase 2 trials progressing towards key milestones, and Roche is establishing a new manufacturing facility for obesity medicines [7] - Zealand Pharma submitted a Marketing Authorization Application for glepaglutide in June 2025, with potential regulatory approval expected in the first half of 2026 [9][22] Leadership and Strategic Direction - The company appointed Utpal Singh as Chief Scientific Officer and Steven Johnson as Chief Development Officer to enhance its innovation and development strategies [13] - Zealand Pharma is preparing for a Capital Markets Day in December 2025 to discuss future growth and strategies [17] Upcoming Milestones - Zealand Pharma expects to report topline results from the Phase 2 ZUPREME-1 trial and complete the Phase 2 ZUPREME-2 trial with petrelintide in the first half of 2026 [13] - The company anticipates initiating a Phase 2 trial for dapiglutide in the second half of 2025 [12]

Acquisition and Development - The Fund announced the acquisition of a property at Hiiu St 42, Tallinn, by its subsidiary EfTEN Hiiu OÜ, with plans to partially reconstruct it into an elderly care home named "Nõmme Südamekodu," which could accommodate up to 170 residents [1] - Following the acquisition, EfTEN Hiiu OÜ collaborated with Nõmme Südamekodu OÜ and design company OÜ SIRKEL&MALL on the design of the elderly care home and initiated a construction procurement process [2] Construction Contract - The best offer for the construction was made by RIS Ehitus OÜ, with whom a construction contract was signed on 13 August 2025, valued at approximately 4 million euros, including VAT [3] - The planned completion date for the elderly care facilities is set for the second quarter of 2026 [3]

Company Overview - Lumen Technologies, Inc. participated in the TD Cowen Communications Infrastructure Summit Conference, with Christopher David Stansbury serving as the Executive VP & CFO [1][2]. Stock Performance - Following the earnings report, Lumen's stock experienced a significant decline of approximately 17%, attributed to a combination of market conditions and investor sentiment [3][4]. - The company is currently facing high leverage at 4.9x, which is a concern for potential investors. However, it is expected that leverage will decrease below 4x upon the completion of the deal with AT&T [4]. Investor Sentiment - There is a notable shift in investor sentiment, with many buy-side investors waiting for leverage to fall below 4x before committing to investments in Lumen [4]. - The existing investor base includes a significant number of passive funds, which may contribute to volatility in stock performance during market downturns [5].